熱門資訊> 正文
Schrödinger报告第四季度业绩
2026-02-26 05:24
- Schrödinger press release (SDGR): Q4 Revenue of $87.2M (-1.2% Y/Y) beats by $3.54M.
- Software revenue was $69.3 million, a 13% decrease, primarily due to the accelerated recognition of upfront revenue from multi-year agreements signed in 2024, partially offset by higher hosted revenue.
- Drug discovery revenue was $18.0 million compared to $8.7 million.
- Software gross margin was 81%.
- Operating expenses were $74.5 million, a 12.2% decrease.
- Other income, which includes gains/losses on equity investments, changes in fair value of such investments and interest income/expense, was $50.1 million.
- Net income for the fourth quarter was $32.5 million, compared to a net loss of $40.2 million in the fourth quarter of 2024.
More on Schrödinger
- Unlocking Hidden Value In Schrodinger's Box
- OpenAI considers backing AI-led drug discovery firms: report
- Eli Lilly in pact with Schrödinger, Revvity for AI-driven drug discovery
- Seeking Alpha’s Quant Rating on Schrödinger
- Historical earnings data for Schrödinger
風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。